BI Asset Management Fondsmaeglerselskab A S Invests $3.66 Million in GSK PLC Sponsored ADR $GSK

Key Points

• BI Asset Management Fondsmaeglerselskab A S has invested approximately $3.66 million in GSK PLC Sponsored ADR, acquiring 94,564 shares during the first quarter.
• GSK's latest earnings report showed earnings per share of $1.23, surpassing analyst expectations of $1.12, alongside a revenue of $10.64 billion.
• The company has announced a quarterly dividend payment of $0.4206 per share, with a 4.2% dividend yield based on an annualized rate of $1.68.

BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 94,564 shares of the pharmaceutical company's stock, valued at approximately $3,663,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. HHM Wealth Advisors LLC lifted its holdings in GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after buying an additional 460 shares in the last quarter. Costello Asset Management INC acquired a new stake in GSK during the 1st quarter worth $31,000. Richardson Financial Services Inc. increased its holdings in GSK by 127.9% in the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock valued at $33,000 after purchasing an additional 472 shares during the last quarter. Olde Wealth Management LLC acquired a new position in GSK in the first quarter valued at about $36,000. Finally, Cary Street Partners Investment Advisory LLC boosted its stake in GSK by 525.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after acquiring an additional 852 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

Wall Street Analyst Weigh In

GSK has been the subject of a number of recent analyst reports. Berenberg Bank restated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Wall Street Zen upgraded shares of GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Finally, Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Seven investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Reduce" and an average target price of $37.38.

GSK Stock Up 1.1%

NYSE:GSK opened at $40.0570 on Thursday. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $44.67. The firm has a market capitalization of $81.62 billion, a price-to-earnings ratio of 18.54, a price-to-earnings-growth ratio of 1.72 and a beta of 0.51. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. The stock's 50 day moving average price is $38.40 and its two-hundred day moving average price is $38.04.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm's revenue was up 1.3% on a year-over-year basis. During the same period last year, the business earned $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities research analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be paid a dividend of $0.4206 per share. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.2%. GSK's payout ratio is currently 77.78%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.